Bloom Burton Has Strong Outlook for BioSyent FY2025 Earnings

BioSyent Inc. (CVE:RX) – Investment analysts at Bloom Burton increased their FY2025 earnings per share estimates for BioSyent in a research report issued to clients and investors on Monday, March 17th. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.81 per share for the year, up from their prior forecast of $0.80. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.94 EPS.

BioSyent Trading Down 0.2 %

Shares of RX stock opened at C$11.23 on Tuesday. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91. The stock’s 50 day simple moving average is C$11.03 and its two-hundred day simple moving average is C$11.11. BioSyent has a 1 year low of C$8.24 and a 1 year high of C$12.13. The company has a market cap of C$128.44 million, a PE ratio of 18.23 and a beta of 0.93.

Insider Transactions at BioSyent

In other news, insider FAX Capital Corp. sold 112,400 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total value of C$1,267,557.28. Company insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.